DNAH7: A Potential Drug Target and Biomarker (G56171)

Target Name: DNAH7

NCBI ID: G56171

DNAH7

DNAH7: A Potential Drug Target and Biomarker

Introduction

DNAH7 (DKFZp686C09101) is a gene that encodes a protein known as DNAH7, which plays a critical role in cellular processes such as DNA replication, repair, and apoptosis. DNAH7 has also been shown to be involved in various signaling pathways, including the regulation of cell adhesion, migration, and invasion.

The discovery and characterization of DNAH7 as a potential drug target and biomarker has significant implications for the development of new therapeutic approaches for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

Potential Drug Target

DNAH7 has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for the growth, survival, and progression of cancer cells. For example, studies have shown that DNAH7 is involved in the regulation of cell cycle progression, which is a critical step in the development of cancer cells. DNAH7 has also been shown to play a role in the regulation of apoptosis, which is the process by which cells undergo programmed cell death, and this is crucial for the control of cancer cell growth and survival.

Furthermore, DNAH7 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. This is a critical process for the growth and progression of many diseases, including cancer. Therefore, targeting DNAH7 with drugs that can inhibit its activity may be an effective way to treat cancer.

Biomarker

DNAH7 has also been identified as a potential biomarker for various diseases, including cancer. This is because its expression has been shown to be regulated in a variety of tissues and conditions, including cancer. For example, studies have shown that DNAH7 is downregulated in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, DNAH7 has been shown to be involved in the regulation of cellular processes that are critical for cancer cell growth and survival, such as cell cycle progression and apoptosis.

Therefore, DNAH7 may be an attractive biomarker for the diagnosis and prognosis of cancer. It could also be a useful target for drug development in cancer.

Conclusion

In conclusion, DNAH7 is a gene that has significant implications for the development of new therapeutic approaches for various diseases, including cancer. Its involvement in various cellular processes, including cell cycle progression, apoptosis, and angiogenesis makes it an attractive potential drug target. Furthermore , its potential as a biomarker for cancer makes it an important step in the development of new diagnostic tools and therapies for this disease.

Targeting DNAH7 with drugs that can inhibit its activity may be an effective way to treat cancer and other diseases. Further research is needed to fully understand the role of DNAH7 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Dynein Axonemal Heavy Chain 7

Functions: Force generating protein of respiratory cilia. Produces force towards the minus ends of microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP (By similarity)

The "DNAH7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAH7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets